Equibles does not estimate personal net worth.
Get an email with a short summary when Inovio Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get INO alertsSteve Egge has spoken on 3 earnings calls across 1 company, most recently for Inovio Pharmaceuticals, Inc. on August 12, 2026. Inovio Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inovio Pharmaceuticals, Inc. includes Jacqueline E. Shea (CEO, COO and Board Member), Jacqueline Shea (CEO, COO and Board Member), Simon X. Benito (Chairman and Board Member) and 7 others.
“We're excited about the opportunity to bring 3107 to patients who are waiting for new treatment options. We see a significant unmet need in the market for alternatives to surgery, and certainly the early uptake of papzimios validates this unmet need.”
“On the commercial front, we are continuing to advance our commercial readiness plans in anticipation of a potential U.S. approval in 2026, and we're planning to manage commercialization ourselves with the support of a contract sales organization.”
“The burden of RRP on patients is significant, and there's an urgent need for treatment options that reduce the need for repeated surgery. RRP is characterized by chronic wart-like growths called papilloma that grow in the respiratory tract and can cause difficulty speaking, swallowing, and breathing.”
Source not stated
Biotechnology · Healthcare
